Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

(2010) Nancie M. Archin et al.   PLoS One

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

(2009) I. Sereti et al.   BLOOD

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy

(2009) Maud Mavigner et al.   PLoS One

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study

(2009) Annica Lindkvist et al.   AIDS Research and Therapy

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets

(2007) Veronica D. Gonzalez et al.   JOURNAL OF IMMUNOLOGICAL METHODS